Insulin: What It Actually Does And Why It Matters More Than You Think

If you spend any time in health and fitness spaces, you’ve heard the refrain: optimize your insulin sensitivity. Manage your blood sugar. Watch your glycemic index. The advice is everywhere. The explanations behind it are almost nowhere.

Most discussions of insulin treat it like a single-purpose hormone. It “regulates blood sugar.” End of lesson. Maybe someone mentions insulin resistance if they’re feeling thorough. But the actual biology of what insulin does across virtually every organ system in your body, why chronic dysregulation leads to such a wide range of disease states, and what insulin resistance means at the cellular level? That conversation rarely happens outside of endocrinology textbooks.

This article is an attempt to fix that. We’re going to walk through insulin’s mechanisms across the body, covering how it handles glucose, fat, and protein, what it does in the brain, how it interacts with inflammation, and why it shows up in aging research. Not because understanding these pathways will replace medical advice (it won’t, and shouldn’t), but because you can’t make informed decisions about your health if the most you’ve ever been told about one of the body’s most important signaling molecules is “it lowers blood sugar.”

A necessary disclaimer: If you have been diagnosed with diabetes (type 1 or type 2), prediabetes, or any condition involving insulin dysregulation, work with an endocrinologist or qualified medical professional. This article is educational. It is not a treatment plan, a diagnostic tool, or a substitute for clinical care. Pathological states change how these mechanisms operate, and managing them requires individualized medical supervision, not internet research.

What insulin actually is

Insulin is a peptide hormone produced by the beta cells of the pancreatic islets of Langerhans. It was first isolated in 1921 by a team at the University of Toronto (Banting, Best, Collip, and Macleod, though the credit has been disputed ever since), and its clinical availability transformed type 1 diabetes from a death sentence into a manageable condition. Before injectable insulin, type 1 diabetics survived at best a year or two on brutal starvation diets.

The hormone itself is relatively small, consisting of 51 amino acids arranged in two chains (A and B) connected by disulfide bonds. It’s synthesized as a larger precursor called preproinsulin, which gets processed in the endoplasmic reticulum into proinsulin, and then cleaved into mature insulin and C-peptide in the Golgi apparatus.¹ C-peptide, once thought to be biologically inert, turns out to have its own signaling roles, but that’s a separate discussion.

What matters here is how insulin secretion works, because it’s not a simple on/off switch.

The biphasic insulin response

When you eat and blood glucose rises, beta cells respond in two distinct phases. The first phase is rapid, occurring within minutes. Preformed insulin stored in granules near the cell membrane gets dumped into the bloodstream almost immediately. This first-phase response is critical for suppressing hepatic (liver) glucose output, essentially telling your liver to stop releasing its own glucose stores because exogenous glucose is arriving.

The second phase is slower and sustained. It involves the synthesis and release of new insulin over the following hours, calibrated to the ongoing glucose load.²

Here’s why this matters clinically: loss of the first-phase insulin response is one of the earliest detectable abnormalities in the progression toward type 2 diabetes. It can be measured years before fasting glucose or HbA1c levels look abnormal on standard lab tests. The standard screening metrics miss early dysfunction because they’re measuring the wrong thing at the wrong time.

Glucose metabolism: the job everyone knows about

Insulin’s best-known function is facilitating glucose uptake from the bloodstream into cells. But even this “simple” function involves a signaling cascade that most discussions skip over entirely.

When insulin binds to its receptor on the surface of a cell (a tyrosine kinase receptor), it triggers autophosphorylation of the receptor’s intracellular domain. This activates a signaling cascade through insulin receptor substrates (IRS proteins), which in turn activate phosphoinositide 3-kinase (PI3K), which generates PIP3, which activates Akt (also called protein kinase B). Akt then stimulates the translocation of GLUT4 glucose transporters from intracellular vesicles to the cell surface.³

That last step is the actual mechanism of glucose uptake. Without insulin signaling, GLUT4 transporters sit inside the cell doing nothing. With it, they move to the membrane and act as channels for glucose to enter. This is why insulin is required for glucose uptake in skeletal muscle and adipose tissue. (The brain, notably, uses GLUT1 and GLUT3 transporters that don’t depend on insulin for baseline glucose uptake, though insulin still has important effects there, which we’ll get to.)

But glucose uptake is only part of the story. Insulin simultaneously:

Promotes glycogen synthesis. Once glucose is inside muscle and liver cells, insulin activates glycogen synthase, which converts glucose into glycogen for storage. Your liver can store roughly 100-120 grams of glycogen; skeletal muscle stores considerably more, around 400-500 grams in a trained individual.⁴

Suppresses hepatic glucose production. Your liver is constantly producing glucose through gluconeogenesis (making new glucose from non-carbohydrate substrates like lactate, amino acids, and glycerol) and glycogenolysis (breaking down stored glycogen). Insulin inhibits both processes. When insulin signaling fails to suppress hepatic glucose output, you get elevated fasting blood glucose even if you haven’t eaten anything. This is a hallmark of hepatic insulin resistance.

Suppresses glycogen breakdown. Insulin inhibits glycogen phosphorylase, the enzyme that breaks glycogen back down into glucose. This is a coordinated system: insulin simultaneously promotes storage and inhibits release.

The net effect is that blood glucose levels drop. But framing insulin’s role as “lowering blood sugar” is like saying a thermostat’s role is “turning off the heater.” Technically accurate. Completely insufficient for understanding the system.

Fat metabolism: it’s more complicated than “insulin makes you fat”

Insulin has major effects on lipid metabolism, and this is where popular health discourse gets particularly sloppy.

Lipogenesis

Insulin promotes de novo lipogenesis (the creation of new fat) in the liver and, to a lesser extent, in adipose tissue. It does this primarily by activating sterol regulatory element-binding protein 1c (SREBP-1c), a transcription factor that upregulates genes involved in fatty acid synthesis.⁵ Insulin also activates acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in fatty acid synthesis.

Inhibition of lipolysis

Simultaneously, insulin suppresses the breakdown of stored fat. It does this by activating phosphodiesterase 3B (PDE3B), which degrades cyclic AMP (cAMP). Since cAMP is what activates hormone-sensitive lipase (HSL), the enzyme responsible for breaking triglycerides down into free fatty acids, reducing cAMP means less fat breakdown.⁶

So does insulin “make you fat”?

This is where the nuance lives. Insulin promotes fat storage and inhibits fat breakdown. That’s real biology. But the popular conclusion that “high insulin = fat gain” misses the context entirely.

Insulin levels are supposed to rise after you eat. That’s the normal physiological response. The rise in insulin after a meal promotes nutrient storage. When insulin falls between meals and during fasting, fat breakdown resumes. In a healthy system, there’s a rhythm: store, then release, store, then release.

The problem isn’t insulin doing its job. The problem is when insulin stays chronically elevated (hyperinsulinemia), often as a compensatory response to developing insulin resistance. When insulin never drops low enough for long enough, fat breakdown stays suppressed, and the system gets stuck in storage mode. This is a metabolic dysfunction, not an indictment of the hormone itself.

People who vilify insulin for causing fat gain are blaming the firefighter for the fire. The real questions are about why insulin stays elevated and how to restore the normal cycle. Insulin resistance and chronic caloric surplus are the usual suspects, but sleep deprivation, chronic stress, and specific dietary patterns all contribute too. For a deeper look at how dietary fiber affects this process by slowing glucose absorption and blunting postprandial insulin spikes, see our article on psyllium husk fiber.

Protein metabolism and muscle growth

Insulin’s role in muscle protein synthesis gets far less attention than it deserves, given how much the fitness community talks about “anabolic” supplements.

Insulin is genuinely anabolic. It promotes muscle protein synthesis through activation of the PI3K/Akt/mTOR pathway. mTOR (mechanistic target of rapamycin) is a kinase complex that acts as a master regulator of cell growth. When mTOR is activated, it phosphorylates downstream targets like p70S6K and 4E-BP1, which initiate the translation of mRNA into new proteins.⁷

However, insulin alone isn’t sufficient for maximal muscle protein synthesis. Research consistently shows that you need adequate amino acid availability, particularly leucine, for mTOR to be fully activated. Insulin’s primary anabolic contribution in muscle may actually be anti-catabolic: it suppresses protein breakdown more potently than it stimulates protein synthesis.⁸

This distinction matters. After resistance training, muscle protein synthesis increases whether or not insulin is elevated, as long as amino acids are present. But muscle protein breakdown is significantly reduced when insulin is present. The net protein balance (synthesis minus breakdown) improves with insulin primarily because of the anti-catabolic effect.

For athletes and anyone interested in body composition, the practical implication is that post-workout nutrition matters less because of insulin’s anabolic effect and more because of its protein-sparing effect. This is also why creatine is interesting in this context. Animal studies suggest creatine may enhance glucose uptake into muscle cells through mechanisms that partially overlap with insulin signaling (GLUT4 translocation), though the human evidence is still limited. Regardless of the exact mechanism, creatine has consistently shown benefits for lean mass in clinical research.

We’ll come back to mTOR in the section on aging, because its role there is considerably less benign.

Insulin in the brain

For decades, the brain was considered “insulin-independent” because it doesn’t rely on insulin for baseline glucose uptake. Neurons primarily use GLUT1 and GLUT3 transporters, which function regardless of insulin status. This led to the assumption that insulin didn’t do much in the central nervous system.

That assumption was wrong.

Insulin receptors are densely distributed throughout the brain. The hippocampus has a high concentration, which matters because that’s where memory consolidation happens. The hypothalamus is loaded with them too, and it’s the region responsible for appetite and energy homeostasis. The cortex also expresses insulin receptors, and cortical insulin signaling appears to influence executive function and decision-making, though that research is less developed than the work on the hippocampus and hypothalamus.⁹ Insulin crosses the blood-brain barrier via a saturable, receptor-mediated transport system, and its effects in the brain are distinct from its peripheral metabolic roles.

Appetite regulation

In the hypothalamus, insulin acts as an anorexigenic signal, meaning it suppresses appetite. This is part of a feedback loop: after you eat, rising insulin tells your brain that energy is arriving and that you can reduce food-seeking behavior. Insulin works alongside leptin in this capacity, and the two hormones have overlapping but distinct signaling pathways in the arcuate nucleus.

When the brain becomes resistant to insulin’s signal (central insulin resistance), this feedback loop degrades. The brain doesn’t “hear” that energy has arrived, appetite suppression weakens, and the drive to eat persists even when caloric needs have been met. This is one reason why insulin resistance and weight gain tend to compound each other. Our article on GLP-1 boosters covers another piece of this appetite regulation puzzle, since GLP-1 is an incretin hormone that works in concert with insulin signaling.

Cognition and memory

Insulin signaling in the hippocampus plays a direct role in synaptic plasticity, the cellular mechanism underlying learning and memory. Insulin modulates long-term potentiation (LTP) and long-term depression (LTD) at synapses, processes that are fundamental to memory formation.¹⁰

This has led to significant interest in what some researchers have termed “type 3 diabetes,” a controversial but increasingly investigated hypothesis that Alzheimer’s disease is, in part, a form of brain-specific insulin resistance. The evidence supporting this connection includes the finding that Alzheimer’s brains show reduced insulin receptor expression, impaired insulin signaling through the PI3K/Akt pathway, and increased phosphorylation of tau protein (a hallmark of Alzheimer’s pathology) in neurons with insulin signaling deficits.¹¹

Intranasal insulin delivery has shown preliminary cognitive benefits in patients with mild cognitive impairment and early Alzheimer’s in small clinical trials, though larger confirmatory studies are ongoing.¹²

If the “type 3 diabetes” hypothesis holds up, it means metabolic health and cognitive decline are linked at a mechanistic level, not just a correlational one. And insulin sits at the center of that link.

Inflammation and immune function

Insulin has anti-inflammatory properties that are often overlooked in favor of its metabolic roles. In endothelial cells and macrophages, insulin suppresses NF-κB, a transcription factor that drives expression of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6.¹³

Insulin also promotes the production of nitric oxide (NO) in vascular endothelium through the PI3K/Akt/eNOS pathway. Nitric oxide is a vasodilator and has anti-inflammatory, anti-thrombotic properties. This is one reason why insulin resistance is so strongly associated with cardiovascular disease: when insulin signaling fails in blood vessels, you lose this protective NO production.

Here’s where it gets circular in a bad way. Chronic inflammation itself causes insulin resistance. Pro-inflammatory cytokines like TNF-α activate serine kinases (particularly JNK and IKKβ) that phosphorylate insulin receptor substrate-1 (IRS-1) at serine residues instead of tyrosine residues. Serine phosphorylation of IRS-1 blocks the insulin signaling cascade.¹⁴

So: insulin resistance leads to increased inflammation, and increased inflammation leads to more insulin resistance. This is a positive feedback loop, and it’s one of the reasons metabolic dysfunction is so hard to reverse once it gets established. Visceral adipose tissue (belly fat) is a major contributor here, because it’s metabolically active tissue that secretes pro-inflammatory adipokines, which further drive the cycle.

Magnesium plays a role in this cycle as well. It’s required for proper insulin receptor tyrosine kinase activity, and magnesium deficiency, which is common, is independently associated with both insulin resistance and elevated inflammatory markers. Vitamin D shows up here too, though the picture is muddier. Vitamin D receptors are expressed on pancreatic beta cells, and deficiency has been associated with impaired insulin secretion and increased insulin resistance in multiple observational studies, though intervention trials have been mixed.

Aging, longevity, and the mTOR paradox

This is where insulin biology gets philosophically interesting, because the same pathway that keeps you alive and helps you build muscle may also be accelerating your aging.

The insulin/IGF-1 signaling axis

Some of the most replicated findings in longevity research come from studies on the insulin/IGF-1 signaling (IIS) pathway. Across species from C. elegans to Drosophila to mice, reduced IIS signaling consistently extends lifespan.¹⁵ The daf-2 mutants in C. elegans, which have reduced insulin receptor function, live up to twice as long as wild-type worms. Dwarf mice with reduced growth hormone and IGF-1 signaling (Ames dwarf, Snell dwarf) are among the longest-lived mouse models ever documented.

The mechanism appears to involve the downstream targets of insulin signaling, particularly mTOR and FOXO transcription factors.

mTOR: the double-edged sword

We introduced mTOR earlier as a driver of muscle protein synthesis. That’s its anabolic role, and it’s genuinely useful for growth, repair, and adaptation to exercise. But mTOR also suppresses autophagy, the cellular housekeeping process that clears damaged organelles, misfolded proteins, and other cellular debris.¹⁶

When mTOR is chronically activated (by persistent insulin signaling, amino acid excess, or both), autophagy stays suppressed. Damaged cellular components accumulate. Senescent cells persist instead of being cleared. Over time, this accelerates the kind of cellular deterioration associated with aging: proteins misfold and aren’t recycled, mitochondria lose efficiency, and the genome accumulates damage that would otherwise be repaired during periods of lower mTOR activity.

This is the paradox: insulin-mediated mTOR activation builds muscle and supports tissue repair in the short term, but chronic mTOR activation appears to accelerate the biological processes underlying aging. Caloric restriction, which is the most robust intervention for extending lifespan in animal models, works in part by reducing insulin and mTOR signaling and activating AMPK and autophagy.

AMPK: the counterbalance

AMP-activated protein kinase (AMPK) functions as mTOR’s counterweight. AMPK is activated by low energy states (low ATP, fasting, exercise) and promotes catabolic processes: fat oxidation, glucose uptake, mitochondrial biogenesis, and autophagy. It also directly inhibits mTOR.

The interplay between insulin/mTOR and AMPK creates a metabolic switch. After a meal, insulin is high, mTOR is active, AMPK is suppressed, and the body prioritizes growth and storage. Between meals, during fasting, or after exercise, that picture inverts. Insulin drops, AMPK takes over, mTOR quiets down, and the body shifts into cleanup and repair mode.

The longevity implications of this switch are why time-restricted feeding and exercise both show benefits for metabolic health that go beyond simple calorie math. They create periods of low insulin and active AMPK, allowing autophagy and cellular maintenance to proceed.

Insulin resistance: what’s actually happening at the cellular level

We’ve referenced insulin resistance throughout this article, but it’s worth examining the cellular mechanics in detail, because “your cells stop responding to insulin” is a dramatic oversimplification.

The lipid overflow hypothesis

One of the leading models of insulin resistance development involves ectopic lipid accumulation. When adipose tissue reaches its storage capacity (which varies enormously between individuals due to genetics), excess lipids spill over into tissues that aren’t designed for fat storage: the liver, skeletal muscle, and pancreas.¹⁷

In these tissues, lipid intermediates, particularly diacylglycerols (DAGs) and ceramides, accumulate. DAGs activate protein kinase C (PKC) isoforms, which phosphorylate IRS-1 at serine residues, blocking the insulin signaling cascade at one of its earliest steps.¹⁸ This is mechanistically distinct from the inflammation-driven pathway described earlier (which works through JNK and IKKβ), but the end result is the same: insulin signaling gets interrupted at the IRS-1 level.

Endoplasmic reticulum stress

The endoplasmic reticulum (ER) is where proteins are folded into their functional shapes. When cells are overwhelmed by nutrient excess, the ER gets backlogged. Misfolded proteins accumulate, triggering the unfolded protein response (UPR). Chronic UPR activation impairs insulin signaling through multiple mechanisms, including activation of JNK (which, again, serine-phosphorylates IRS-1) and increased production of reactive oxygen species.¹⁹

Mitochondrial dysfunction

Mitochondria in insulin-resistant tissues show impaired oxidative capacity. Whether this is a cause or consequence of insulin resistance is still debated, but the evidence increasingly suggests it’s both. Reduced mitochondrial fatty acid oxidation leads to intracellular lipid accumulation (feeding back into the DAG/PKC pathway), while insulin resistance itself impairs mitochondrial biogenesis through reduced PGC-1α signaling.

The progression to type 2 diabetes

Insulin resistance alone doesn’t cause diabetes. For years, even decades, pancreatic beta cells compensate by producing more insulin. Blood glucose stays normal. Standard lab tests look fine.

But the beta cells aren’t immortal. Chronic hyperinsulinemia, combined with glucotoxicity (elevated glucose), lipotoxicity (elevated lipids), and ER stress, eventually leads to beta cell exhaustion and apoptosis. Insulin production declines. Blood glucose rises. Now it shows up on lab tests. Now you get a diagnosis.

The progression from insulin resistance to compensatory hyperinsulinemia to beta cell failure to overt type 2 diabetes can take a decade or more. During most of that window, conventional screening doesn’t catch it. This is why some clinicians advocate for fasting insulin and HOMA-IR testing as earlier markers of metabolic dysfunction, though these aren’t yet part of standard practice in most primary care settings.

Zinc is worth mentioning here because it plays a direct role in insulin biology. Zinc is required for insulin crystallization and storage in beta cell granules, and zinc transporters (particularly ZnT8) on beta cells are essential for normal insulin secretion. Zinc deficiency impairs both insulin synthesis and secretion.

Tying it together

Insulin is not a blood sugar hormone. Calling it one is like describing the internet as “the thing that sends emails.” It’s technically not wrong, but it misses almost everything that matters.

The popular advice to “optimize insulin sensitivity” isn’t wrong, exactly. But it’s hollow without understanding what you’re optimizing. Insulin sensitivity in skeletal muscle is a different physiological question than insulin sensitivity in the liver, which is different from insulin sensitivity in the brain or in blood vessels. They don’t all respond to the same interventions, and they don’t all break down at the same rate.

Understanding these mechanisms won’t make you your own endocrinologist. But it gives you a framework for evaluating the claims that come at you constantly from the health and fitness space. When someone tells you to “spike your insulin post-workout for gains,” you can evaluate what they’re actually proposing at a molecular level and what the tradeoffs might be. When someone tells you carbs are poison because they raise insulin, you can recognize why that framing collapses under even basic scrutiny.

The mechanisms matter. That’s the whole point.

For a broader look at how nutrition science informs evidence-based health decisions, see our nutrition overview. And if you’re interested in how supplements interact with these pathways, our article on the science of supplements and bioavailability provide the foundational context for understanding which interventions actually have mechanistic support.

References

Questions or Comments?

If you have a question or comment about this article, feel free to leave it below. All comments are moderated for clarity, accuracy, and relevance.

Insulin: What It Actually Does and Why It Matters More Than You Think